Abstract
Subdivision of CLL into typical and atypical subtypes, as proposed by the FAB group in 1989, is not yet widely accepted and its clinical significance is still debated. In recent years, however, a strong correlation was found between atypical morphology, trisomy 12 and an aberrant immunophenotype. In the first part of this review we discuss current concepts and generally accepted data on morphology, immunophenotype, genetic abnormalities, clinical features and prognostic factors in CLL. Subsequently, based on our own series and other recently published data, we analyse the validity and clinical impact of classifying CLL into typical and atypical entities and demonstrate that they may represent two closely related but different entities.